Using Big Data in genetic autism research

Page 1 of 1 [ 2 posts ] 

ASPartOfMe
Veteran
Veteran

User avatar

Joined: 25 Aug 2013
Age: 63
Gender: Male
Posts: 25,210
Location: Long Island, New York

07 Jul 2017, 3:38 am

Using Big Data to Hack Autism Researchers scour datasets for clues to autism—needles in a genetic haystack of 20,000 people

Quote:
In April 2007, Wigler and his then colleague, Jonathan Sebat, reported that ‘de novo’ mutations—those that arise spontaneously instead of being inherited—occur more often in people with autism than in typical people. The mutations they noted were in the form of ‘copy number variants’ (CNVs), deletions or duplications of long stretches of DNA. CNVs crop up frequently in cancer, an earlier focus of Wigler’s work. But his find that they are also involved in autism came as a surprise to those in the field. “Genetics was striking out with other efforts based on transmission and inheritance,” Wigler says. “In that vacuum, the new idea was quickly embraced.”

The discovery fast led to further advances. Focusing primarily on de novomutations, three teams of scientists, including one led by Wigler, began hunting for genes that contribute to autism. Their approach was efficient: Rather than looking at the entire genome, they scoured the 2 percent that encodes proteins, called the exome. And they looked specifically at simplex families, which have a single child with autism and unaffected parents and siblings. The premise was that comparing the exomes of the family members might expose de novomutations in the child with autism. The approach yielded a bumper crop: Based on data from more than 600 families, the teams together predicted that there are hundreds of autism genes. They identified six as leading candidates. Some of the genes identified at the time — CHD8, DYRK1A, SCN2A — quickly became hot areas of research.

In 2014, the number of strong candidates jumped higher. In two massive studies analyzing the sequences of more than 20,000 people, researchers linked 50 genes to autism with high confidence. Wigler’s team looked at simplex families and found rare de novo mutations in 27 genes. In the second study, researchers screened for both inherited and de novo mutations and implicated 33 genes. The two studies identified 10 genes in common.

Two years ago, the tally of autism gene candidates shot up again. Deploying statistical wizardry to combine the data on de novo and inherited mutations, along with CNV data from the Autism Genome Project, researchers pinpointed 65 genes and six CNVs as being key to autism. They also identified 28 genes that they could say with near certainty are ‘autism genes.’

These advances establish beyond doubt that autism is firmly rooted in biology. “More and more, we are erasing this idea of autism being a stigmatizing psychiatric disorder, and I think this is true for the whole of psychiatry,” Sanders says. “These are genetic disorders; this is a consequence of biology, which can be understood, and where traction can be made.”

This is just the start, however. As scientists enter the next chapter of autism genetics, they are figuring out how to build on what they have learned, using better sequencing tools and statistics, bigger datasets and more robust models. For example, they are looking for common variants—which are found in more than 1 percent of the population but may contribute to autism when inherited en masse. And they are also starting to look beyond the exome to the remaining 98 percent of the genome they have largely neglected thus far.

“Most of the genetic advances fall into a category of large-effect-size de novovariants, which is only one piece of the puzzle,” says Daniel Geschwind, professor of human genetics at the University of California, Los Angeles. It’s an important piece, but one that still cannot explain why autism clusters in families, for instance, or why close relatives of people with autism often share some of the condition’s traits.

So how much of autism’s genetic architecture have scientists uncovered? Current estimates suggest that rare mutations, whetherde novo or inherited, contribute to the condition somewhere between 10 and 30 percent of the time. Before the recent spate of discoveries, the proportion of individuals whose autism had a known genetic cause was only 2 to 3 percent—much of that from rare related genetic syndromes, such asfragile X syndrome and tuberous sclerosis complex, which stem from mutations in a single known gene. These syndromes often involve some core features of autism, along with their own set of characteristic traits, and intellectual disability.

“Two generations ago, at least 75 percent of the time autism was comorbid with severe intellectual disability and other neurodevelopmental abnormalities,” says Mark Daly, associate professor of medicine at Harvard University. “It was also a much rarer diagnosis.”

The large increase in diagnoses in recent decades “overwhelmingly” reflects cases at the mild end of the spectrum, Daly says, creating a new challenge. “The genetics of autism has us wrestling with the fact that rare mutations, and especially these spontaneously arising ones, are the strongest risk factors,” he says. “But at the same time, there’s a majority of cases now that don’t have any of those high-impact risk factors.”

Because common variants have small effects individually, they are difficult to find, but multiple studies suggest that they play a major role in autism risk. In a 2014 study, for instance, researchers used statistical tools to estimate the heritability of autism from the amount of common variation shared by unrelated people with autism. They applied the method to data from more than 3,000 people in Sweden’s national health registry. Their calculations indicated that common variants account for 49 percent of the risk for autism in the general population; rare variants, equal parts de novo and inherited, explain 6 percent. Some scientists dispute these figures, but it’s clear that common variants, rare inherited variants and spontaneous mutations all play a part in autism.

Common variants may turn out to be more relevant at the milder end of the spectrum than in those who are severely affected. “The people who have de novo mutations, en masse, tend to have lower intelligence quotients and more cognitive problems,” Sanders says.

The genes identified so far have hinted at a handful of underlying mechanisms that contribute to autism. Most of them seem to be involved in three broad categories of tasks: maintaining the function of synapses, or the connections between neurons; controlling the expression of genes; and modifying chromatin, structures of DNA wound around protein ‘spools’ called histones. Chromatin determines which stretches of DNA can be read and so influences gene expression.

Using gene expression maps, such as the BrainSpan Atlas, researchers have traced when and where autism genes are active in the brain. They have found that many of the genes, CHD8 and SCN2A included, are expressed in parts of the cortex during mid- to late fetal development—which happens to be the peak period when neurons are forming. “We don’t really understand it yet, but they’re more likely than not to disrupt fetal brain development in mid-gestation,” Geschwind says. That timing suggests they interfere with processes that are critical to setting up the cortex, including which types of cells form and where in the brain they migrate. If the cortex isn’t set up right, he says, you create ongoing problems with how neurons communicate, among other important functions. Within the next few years, he says, researchers will have a refined understanding of the neurons and circuits affected.

Work in animal and cell models reveals similar problems with the genesis, structure and fate of new neurons and the connections between them. In some cell and animal models of syndromic forms of autism, scientists have managed to at least partially correct some of these problems with drugs. The unrealized promise of these findings is that some traits of autism may ultimately prove reversible, even in adults.

“The idea that there’s something plastic here, not set in stone at birth, is very important,” says Matthew State, chair of psychiatry at the University of California, San Francisco, and lead investigator on many of the big autism genetics studies.


In the meantime, genetic discoveries have delivered some immediate benefits for people with the condition. “If you go into a clinic today, there’s about a 10 percent chance of you getting a genetic diagnosis, and I would expect to find evidence which was suggestive in about another 5 to 10 percent,” Sanders says. “We can’t then turn round and say, ‘Here’s your cure,’ but what we can do, at least, is put people in touch with other people with that same mutation.” Becoming part of such a group gives people a better idea about what the future holds for them and provides them with support and understanding.

Genetic diagnoses can also help families make decisions about family planning and treatment options

Stem cells and emerging technologies such as brain organoids—so called ‘mini-brains’ in a dish—could afford researchers a prime opportunity to study the effects of genetic variation in human neurons. Faced with the limitations of mouse models in studying a condition characterized by behavioral problems, some teams are also turning to monkeys, which enable them to study more complex social interactions. “Something we should be doing for the future is taking the precise mutations we find in humans and making those in primates,” Wigler says.

These days, Wigler is on to another big idea: risk modifiers. Rare variants strongly associated with autism also occur in people without autism—especially women. Researchers know that mutations can contribute to autism by amplifying or attenuating the effects of other genes, so it’s feasible that two mutations could cancel each other out. But few teams have looked into these combinations as yet. “People talk about autism as being an additive disorder,” Wigler says, “but nobody’s really looking at additivity.”

Bolding mine
My takeaway is that the idea using genetics research with the goal of eliminating autism is alive and well. A cure is a long way off but but a partial cure for some is closer then most people think as is using genetic makeup to abort fetuses suspected of being autistic.


_________________
Professionally Identified and joined WP August 26, 2013
DSM 5: Autism Spectrum Disorder, DSM IV: Aspergers Moderate Severity.

“My autism is not a superpower. It also isn’t some kind of god-forsaken, endless fountain of suffering inflicted on my family. It’s just part of who I am as a person”. - Sara Luterman


1Biggles1
Veteran
Veteran

Joined: 2 Apr 2017
Gender: Male
Posts: 1,869

07 Jul 2017, 4:23 am

Intriguing.